These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

861 related articles for article (PubMed ID: 31831026)

  • 1. Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma.
    Lewitzki V; Klement RJ; Kosmala R; Lisowski D; Flentje M; Polat B
    Radiat Oncol; 2019 Dec; 14(1):227. PubMed ID: 31831026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accelerated hyper-versus normofractionated radiochemotherapy with temozolomide in patients with glioblastoma: a multicenter retrospective analysis.
    Klement RJ; Popp I; Kaul D; Ehret F; Grosu AL; Polat B; Sweeney RA; Lewitzki V
    J Neurooncol; 2022 Jan; 156(2):407-417. PubMed ID: 34940951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accelerated hyperfractionation plus temozolomide in glioblastoma.
    Kaul D; Florange J; Badakhshi H; Grün A; Ghadjar P; Exner S; Budach V
    Radiat Oncol; 2016 May; 11():70. PubMed ID: 27209069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiotherapy plus temozolomide in elderly patients with glioblastoma: a "real-life" report.
    Biau J; Chautard E; De Schlichting E; Dupic G; Pereira B; Fogli A; Müller-Barthélémy M; Dalloz P; Khalil T; Dillies AF; Durando X; Godfraind C; Verrelle P
    Radiat Oncol; 2017 Dec; 12(1):197. PubMed ID: 29212499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic implications of the subcellular localization of survivin in glioblastomas treated with radiotherapy plus concomitant and adjuvant temozolomide.
    Saito T; Sugiyama K; Takeshima Y; Amatya VJ; Yamasaki F; Takayasu T; Nosaka R; Muragaki Y; Kawamata T; Kurisu K
    J Neurosurg; 2018 Mar; 128(3):679-684. PubMed ID: 28430038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective comparison of standard and escalated doses of radiotherapy in newly diagnosed glioblastoma patients treated with concurrent and adjuvant temozolomide.
    Guler OC; Yıldırım BA; Önal C; Topkan E
    Indian J Cancer; 2019; 56(1):59-64. PubMed ID: 30950447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiochemotherapy with temozolomide for patients with glioblastoma. Prognostic factors and long-term outcome of unselected patients from a single institution.
    Gerstein J; Franz K; Steinbach JP; Seifert V; Rödel C; Weiss C
    Strahlenther Onkol; 2011 Nov; 187(11):722-8. PubMed ID: 22037649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).
    Mallick S; Kunhiparambath H; Gupta S; Benson R; Sharma S; Laviraj MA; Upadhyay AD; Julka PK; Sharma D; Rath GK
    J Neurooncol; 2018 Oct; 140(1):75-82. PubMed ID: 29936695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
    Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
    Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged survival when temozolomide is added to accelerated radiotherapy for glioblastoma multiforme.
    Guckenberger M; Mayer M; Buttmann M; Vince GH; Sweeney RA; Flentje M
    Strahlenther Onkol; 2011 Sep; 187(9):548-54. PubMed ID: 21858417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Super-early initiation of temozolomide prolongs the survival of glioblastoma patients without gross-total resection: a retrospective cohort study.
    Jiang H; Zeng W; Ren X; Cui Y; Li M; Yang K; Elbaroody M; Lin S
    J Neurooncol; 2019 Aug; 144(1):127-135. PubMed ID: 31175579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience.
    Zhong L; Chen L; Lv S; Li Q; Chen G; Luo W; Zhou P; Li G
    Radiat Oncol; 2019 Jun; 14(1):104. PubMed ID: 31196126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postoperative radiotherapy of glioblastoma multiforme: analysis and critical assessment of different treatment strategies and predictive factors.
    Piroth MD; Gagel B; Pinkawa M; Stanzel S; Asadpour B; Eble MJ
    Strahlenther Onkol; 2007 Dec; 183(12):695-702. PubMed ID: 18040615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study.
    Rapp M; Goeppert M; Felsberg J; Steiger HJ; Sabel M
    Br J Neurosurg; 2013 Aug; 27(4):430-5. PubMed ID: 23418781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Standard dose and dose-escalated radiation therapy are associated with favorable survival in select elderly patients with newly diagnosed glioblastoma.
    Jackson WC; Tsien CI; Junck L; Leung D; Hervey-Jumper S; Orringer D; Heth J; Wahl DR; Spratt DE; Cao Y; Lawrence TS; Kim MM
    J Neurooncol; 2018 May; 138(1):155-162. PubMed ID: 29388034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of hypofractionated radiation therapy in elderly patients with newly diagnosed glioblastoma with poor prognosis.
    Navarria P; Pessina F; Cozzi L; Tomatis S; Reggiori G; Simonelli M; Santoro A; Clerici E; Franzese C; Carta G; Conti Nibali M; Bello L; Scorsetti M
    Tumori; 2019 Feb; 105(1):47-54. PubMed ID: 30131010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
    Shields LB; Shelton BJ; Shearer AJ; Chen L; Sun DA; Parsons S; Bourne TD; LaRocca R; Spalding AC
    Radiat Oncol; 2015 Oct; 10():222. PubMed ID: 26520780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors.
    Birol Sarica F; Tufan K; Cekinmez M; Sen O; Cem Onal H; Mertsoylu H; Topkan E; Pehlivan B; Erdogan B; Nur Altinors M
    J Neurosurg Sci; 2010 Mar; 54(1):7-19. PubMed ID: 20436394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.